A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

LixiLan is a fixed-ratio combination of basal insulin glargine 100 units/ml – marketed on its own as Lantus - matched with the GLP-1 receptor agonist lixisenatide, the active ingredient in ...

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications primarily used to treat type 2 diabetes. GLP-1s work by ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a ...

With sales of around $2.7 billion in 2015, Victoza has dominated the GLP-1 market ... (insulin glargine) in a single product, although this will likely have competition from a rival combo from ...

After 8 months of this combination approach, average total body weight loss was 20.3%, and lean body mass increased by 15% from 59.6% to 68.5%. All patients remained adherent to the GLP-1 ...

This hormone is naturally produced in the intestines and is crucial in regulating glucose by promoting insulin secretion. When GLP-1 is active, it communicates with the brain to reduce hunger and ...

surged ~31% in after-hours trading Thursday after posting preliminary data on weight loss associated with its gastric balloon in combination with Novo Nordisk's (NVO) GLP-1 semaglutide.